In a recent interview, Wayne Brisbane, M.D., discussed new research, presented at the American Urological Association (AUA) conference, which revealed a 15 percent higher AUC for an emerging AI software in detecting seminal vesicle invasion (SVI) in comparison to prostate MRI alone.
Magnetic resonance imaging (MRI) and prostate-specific membrane-antigen positron emission tomography (PSMA PET) both have limitations with respect to the detection of seminal vesicle invasion (SVI) in prostate cancer, noted Wayne Brisbane, M.D., in a recent interview.
“One of the issues is (MRI) is not super sensitive so if there's a small amount of seminal vesicle invasion, it might not be picked up, especially if the tumor volume is very small. But it's still important because we would risk adjust those patients and change their treatment paradigms,” noted Dr. Brisbane, an assistant professor of urology at the University of California-Los Angeles (UCLA). “ … With PSMA, there (are) other challenges. While molecular imaging is very easy to interpret, there is less spatial resolution between the prostate and the seminal vesicle so interpreting seminal vesicle invasion with PSMA and MRI can be challenging.”
However, in a recent lecture at the American Urological Association (AUA) Annual Meeting, Dr. Brisbane discussed key findings from a new study examining the use of the MRI-based artificial intelligence (AI) software Unfold AI (Avenda Health) for detecting SVI in patients with prostate cancer.
In an initial cohort of 147 men who underwent radical prostatectomy (with a 17 percent incidence of SVI), the researchers found that the AI software provided 92 percent sensitivity, 89 percent specificity and a 95 percent area under the receiver operating characteristic curve (AUC), 15 percent higher than the AUC for MRI alone (80 percent).1
“(This) AI (software) was initially trained on (prostate) tumor volume but has found really impressive accuracy for predicting cancers coming out of the prostate or into the seminal vesicles,” noted Dr. Brisbane.
(Editor’s note: For related content, see “Study: PSMA PET/CT More Advantageous than MRI for Locoregional Staging of Prostate Cancer,” “Researchers Unveil PI-QUAL v2 for Prostate MRI Quality Assessments” and “Study Shows PET MRI Offers Better Detection of Localized Prostate Cancer than mpMRI.”)
For more insights from Dr. Brisbane, watch the video below.
Reference
1. Brisbane W, Priester A, Mota SM, et al. Prediction of seminal vesicle invasion using artificial intelligence prostate cancer risk mapping. J Urology. 2025 May 1. https://doi.org/10.1097/01.JU.0001109868.09667.98.20 . Presented at the American Urological Association (AUA) Annual Meeting April 26-29, 2025, Las Vegas.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Large Medicare Study Shows Black Men Less Likely to Receive PET and MRI for Prostate Cancer Imaging
August 1st 2025An analysis of over 749,000 Medicare beneficiaries diagnosed with prostate cancer over a five-year period found that Black men were 13 percent less likely to receive PET imaging and 16 percent less likely to receive MRI in comparison to White men.
The Reading Room Podcast: A Closer Look at Remote MRI Safety, Part 3
August 1st 2025In the third of a three-part podcast episode, Emanuel Kanal, M.D. and Tobias Gilk, MRSO, MRSE, discuss strategies for maintaining the integrity of time-out procedures and communication with remote MRI scanning.
Reducing the Interval Breast Cancer Rate of Screening DBT: Can AI Have an Impact?
August 1st 2025In a retrospective review of screening digital breast tomosynthesis (DBT) exams for over 200 women with interval breast cancers, researchers found that AI provided accurate localization of cancers in 32.6 percent of the cases.
The Reading Room Podcast: A Closer Look at Remote MRI Safety, Part 2
August 1st 2025In the second of a multi-part podcast episode, Emanuel Kanal, M.D. and Tobias Gilk, MRSO, MRSE, share their perspectives on remote MRI safety protocols for ensuring screening accuracy and adherence to conditional implant guidelines as well as a rapid and effective response to adverse events.